This FAQ breaks down the AAP's newest COVID-19, RSV, and influenza recommendations for clinicians who want a quick refresher on what changed for the 2026-2027 season.
News|Articles|October 27, 2025
Our coverage recap from IDWeek 2025
Author(s)Joshua Fitch, Senior Editor
Fact checked by: Morgan Ebert, Executive Editor
Key highlights from the conference included public health, advocacy for vaccines, and artificial intelligence.
Advertisement
Advertisement
Though the
Related to this article
XOCOVA gives pediatricians a new oral option to help prevent COVID-19 after exposure in adolescents aged 12 years and older.
Five rapid developments — new mRNA flu vaccine, CDC director, ACIP/NVAC charters, a vaccine order, and an HHS RFI — roil the 2026 schedule.
Court fight over CDC 2026 childhood vaccine schedule shifts shots to shared decision-making; experts warn lower uptake for Hep A, B, flu, COVID.
New evidence supports influenza, COVID-19, and RSV immunizations for reducing severe respiratory illness and hospitalization.
CDC's 2025 NIS-Teen data show HPV vaccine coverage flat for a fourth year, with rural adolescents 12 points behind urban peers in receiving ≥1 dose.
The AAP's 2026-2027 policy recommends universal vaccination for infants 6-23 months and a risk-based single dose for children 2-18 years.
AAP guidance expands RSV immunization eligibility for children aged 8 through 19 months at high risk of severe disease.
Advertisement
Advertisement